FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311451747> ?p ?o ?g. }

• W4311451747 endingPage "424" @default.
• W4311451747 startingPage "415" @default.
• W4311451747 abstract "COVID-19 has overwhelmed health services globally. Oral antiviral therapies are licensed worldwide, but indications and efficacy rates vary. We aimed to evaluate the safety and efficacy of oral favipiravir in patients hospitalised with COVID-19.We conducted a multicentre, open-label, randomised controlled trial of oral favipiravir in adult patients who were newly admitted to hospital with proven or suspected COVID-19 across five sites in the UK (n=2), Brazil (n=2) and Mexico (n=1). Using a permuted block design, eligible and consenting participants were randomly assigned (1:1) to receive oral favipiravir (1800 mg twice daily for 1 day; 800 mg twice daily for 9 days) plus standard care, or standard care alone. All caregivers and patients were aware of allocation and those analysing data were aware of the treatment groups. The prespecified primary outcome was the time from randomisation to recovery, censored at 28 days, which was assessed using an intention-to-treat approach. Post-hoc analyses were used to assess the efficacy of favipiravir in patients aged younger than 60 years, and in patients aged 60 years and older. The trial was registered with clinicaltrials.gov, NCT04373733.Between May 5, 2020 and May 26, 2021, we assessed 503 patients for eligibility, of whom 499 were randomly assigned to favipiravir and standard care (n=251) or standard care alone (n=248). There was no significant difference between those who received favipiravir and standard care, relative to those who received standard care alone in time to recovery in the overall study population (hazard ratio [HR] 1·06 [95% CI 0·89-1·27]; n=499; p=0·52). Post-hoc analyses showed a faster rate of recovery in patients younger than 60 years who received favipiravir and standard care versus those who had standard care alone (HR 1·35 [1·06-1·72]; n=247; p=0·01). 36 serious adverse events were observed in 27 (11%) of 251 patients administered favipiravir and standard care, and 33 events were observed in 27 (11%) of 248 patients receiving standard care alone, with infectious, respiratory, and cardiovascular events being the most numerous. There was no significant between-group difference in serious adverse events per patient (p=0·87).Favipiravir does not improve clinical outcomes in all patients admitted to hospital with COVID-19, however, patients younger than 60 years might have a beneficial clinical response. The indiscriminate use of favipiravir globally should be cautioned, and further high-quality studies of antiviral agents, and their potential treatment combinations, are warranted in COVID-19.LifeArc and CW+." @default.
• W4311451747 created "2022-12-26" @default.
• W4311451747 creator A5001470555 @default.
• W4311451747 creator A5002630621 @default.
• W4311451747 creator A5003130862 @default.
• W4311451747 creator A5005009174 @default.
• W4311451747 creator A5005806572 @default.
• W4311451747 creator A5006317145 @default.
• W4311451747 creator A5007617508 @default.
• W4311451747 creator A5007876312 @default.
• W4311451747 creator A5008174473 @default.
• W4311451747 creator A5008788766 @default.
• W4311451747 creator A5010478528 @default.
• W4311451747 creator A5012173485 @default.
• W4311451747 creator A5012448389 @default.
• W4311451747 creator A5013008320 @default.
• W4311451747 creator A5013111497 @default.
• W4311451747 creator A5013982734 @default.
• W4311451747 creator A5015037312 @default.
• W4311451747 creator A5018296766 @default.
• W4311451747 creator A5018857104 @default.
• W4311451747 creator A5020426350 @default.
• W4311451747 creator A5021842606 @default.
• W4311451747 creator A5021957943 @default.
• W4311451747 creator A5022230271 @default.
• W4311451747 creator A5023111958 @default.
• W4311451747 creator A5024783432 @default.
• W4311451747 creator A5024845577 @default.
• W4311451747 creator A5024931884 @default.
• W4311451747 creator A5026988583 @default.
• W4311451747 creator A5028833865 @default.
• W4311451747 creator A5029092446 @default.
• W4311451747 creator A5029508707 @default.
• W4311451747 creator A5029682445 @default.
• W4311451747 creator A5031449912 @default.
• W4311451747 creator A5032190653 @default.
• W4311451747 creator A5032252603 @default.
• W4311451747 creator A5032899454 @default.
• W4311451747 creator A5033188653 @default.
• W4311451747 creator A5033524581 @default.
• W4311451747 creator A5035160310 @default.
• W4311451747 creator A5035607041 @default.
• W4311451747 creator A5035647665 @default.
• W4311451747 creator A5035762832 @default.
• W4311451747 creator A5039370351 @default.
• W4311451747 creator A5039809588 @default.
• W4311451747 creator A5040265966 @default.
• W4311451747 creator A5040376588 @default.
• W4311451747 creator A5041053188 @default.
• W4311451747 creator A5041159215 @default.
• W4311451747 creator A5041453127 @default.
• W4311451747 creator A5041543681 @default.
• W4311451747 creator A5041791201 @default.
• W4311451747 creator A5042176782 @default.
• W4311451747 creator A5043738893 @default.
• W4311451747 creator A5043964549 @default.
• W4311451747 creator A5044421600 @default.
• W4311451747 creator A5046032199 @default.
• W4311451747 creator A5046649039 @default.
• W4311451747 creator A5047278563 @default.
• W4311451747 creator A5048050447 @default.
• W4311451747 creator A5048147329 @default.
• W4311451747 creator A5048795001 @default.
• W4311451747 creator A5049288906 @default.
• W4311451747 creator A5050198943 @default.
• W4311451747 creator A5050241854 @default.
• W4311451747 creator A5050901838 @default.
• W4311451747 creator A5051667937 @default.
• W4311451747 creator A5052148998 @default.
• W4311451747 creator A5052473859 @default.
• W4311451747 creator A5052883776 @default.
• W4311451747 creator A5052932941 @default.
• W4311451747 creator A5053857476 @default.
• W4311451747 creator A5055539997 @default.
• W4311451747 creator A5055703239 @default.
• W4311451747 creator A5057560470 @default.
• W4311451747 creator A5057834337 @default.
• W4311451747 creator A5060368284 @default.
• W4311451747 creator A5061894879 @default.
• W4311451747 creator A5064489188 @default.
• W4311451747 creator A5064559452 @default.
• W4311451747 creator A5064579245 @default.
• W4311451747 creator A5065784852 @default.
• W4311451747 creator A5066218661 @default.
• W4311451747 creator A5066802620 @default.
• W4311451747 creator A5066839225 @default.
• W4311451747 creator A5068738541 @default.
• W4311451747 creator A5069513325 @default.
• W4311451747 creator A5070162923 @default.
• W4311451747 creator A5071803986 @default.
• W4311451747 creator A5072207607 @default.
• W4311451747 creator A5074459342 @default.
• W4311451747 creator A5075130388 @default.
• W4311451747 creator A5076517531 @default.
• W4311451747 creator A5078654964 @default.
• W4311451747 creator A5078794673 @default.
• W4311451747 creator A5079217843 @default.
• W4311451747 creator A5080101749 @default.

• next